Abstract
Altered metabolism was first identified in cancer cells by Otto Warburg, who identified a higher reliance on anaerobic glycolysis rather than cellular respiration even in the presence of sufficient oxygen levels, a phenomenon called the Warburg Effect. Deregulated metabolism is now considered a driving hallmark of cancer and an attractive therapeutic target. While a great deal of work is being done to find genetic therapeutic targets that can be used for personalized medicine, current targeted approaches are typically ineffective because tumors are heterogeneous and contain multiple genetic subpopulations. This often precludes a particular targeted molecule from being found on all cells. In contrast to many genetic alterations, dysregulation of metabolism resulting in the need for high amounts of glucose is found in virtually all cancer cells. Targeting metabolism by reducing blood glucose may be a way to inhibit tumor growth since this, to a large extent, should circumvent the inherent problems associated with tumor heterogeneity. Methods that also provide an energy source for normal tissues such as ketones should reduce side effects associated with an overall reduction in blood glucose. The high-fat, low carbohydrate, and protein ketogenic diet (KD) results in reduced blood glucose and increased blood ketones, as does caloric restriction and fasting. In preclinical mouse models of malignant brain tumors, animals fed a KD had increased survival, particularly when used in combination with radiation or chemotherapy. Metabolic modulation through the use of a KD, caloric restriction, or fasting has been found to change the expression of a number of genes and pathways thought to inhibit tumor growth. Metabolic therapy has also recently been explored in other cancer types. In this chapter, we will examine the mechanisms underlying the KD which suggests its potential as an adjuvant therapy for cancer treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, Scheck AC (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 7(5), e36197
Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, Szweda LI, Smith B, Spitz DR, Fath MA (2013) Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res 19(14):3905–3913
Amigo I, Kowaltowski AJ (2014) Dietary restriction in cerebral bioenergetics and redox state. Redox Biol 2:296–304
Anton K, Baehring JM, Mayer T (2012) Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am 26(4):825–853
Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 4:30
Azad N, Zahnow CA, Rudin CM, Baylin SB (2013) The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol 10(5):256–266
Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734
Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT (2012) Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 117(6):1032–1038
Boele FW, Heimans JJ, Aaronson NK, Taphoorn MJ, Postma TJ, Reijneveld JC, Klein M (2013) Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study. J Neurooncol 115(1):87–94
Brennan C (2011) Genomic profiles of glioma. Curr Neurol Neurosci Rep 11(3):291–297
Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4(11), e7752
Cahill GF Jr, Veech RL (2003) Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 114:149–161
Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2(10):881–898
Champ CE, Baserga R, Mishra MV, Jin L, Sotgia F, Lisanti MP, Pestell RG, Dicker AP, Simone NL (2013) Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist 18(1):97–103
Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L, Shi W (2014) Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 117(1):125–131
Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, Morel L, Verrelle P (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 12(5):434–443
Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:17
Cross JH (2013) New research with diets and epilepsy. J Child Neurol 28(8):970–974
Danhier P, De Saedeleer CJ, Karroum O, De PG, Porporato PE, Jordan BF, Gallez B, Sonveaux P (2013) Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications. Semin Radiat Oncol 23(4):262–272
De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, Rabson AB (2011) Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32(9):1381–1387
Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby J, Jacobs M, Pusic A, La SE, Stupp R, Fayers P, Efficace F (2014) The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. Eur J Cancer 50(14):2432–2448
El-Kenawi AE, El-Remessy AB (2013) Angiogenesis Inhibitors in Cancer Therapy: Mechanistic perspective on classification and treatment rationales. Br. J, Pharmacol
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892–3899
Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN (2008) Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26(12):3027–3036
Fan QW, Weiss WA (2010) Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347(279-96):279–296
Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47(1):42–48
Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA (2014) Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. Cancer 10
Fredericks M, Ramsey RB (1978) 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J Neurochem 31(6):1529–1531
Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB (2008) Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68(1):11–19
Fruehauf JP, Meyskens FL Jr (2007) Reactive oxygen species: a breath of life or death? Clin Cancer Res 13(3):789–794
Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, Brem H, Riggins GJ (2009) Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 8(2):386–393
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899
Gil Del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, Xie XJ, Bachoo R, Li L, Habib AA, Burma S (2014) Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma. Clin, Cancer Res
Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, Yun J, Samanamud J, Sims JS, Banu M, Dovas A, Teich AF, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Sims PA, Canoll P (2014) MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A 111(34):12550–12555
Gluschnaider U, Hertz R, Ohayon S, Smeir E, Smets M, Pikarsky E, Bar-Tana J (2014) Long-chain Fatty Acid analogues suppress breast tumorigenesis and progression. Cancer Res 74(23):6991–7002
Group TCGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068
Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB (2012) Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention and therapy. Antioxid Redox Signal 16(11):1295–1322
Haisa M (2013) The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res 41(2):253–264
Harvey AE, Lashinger LM, Otto G, Nunez NP, Hursting SD (2013) Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor-kappaB activation, and inflammation-related gene expression. Mol Carcinog 52(12):997–1006
Heydari AR, Unnikrishnan A, Lucente LV, Richardson A (2007) Caloric restriction and genomic stability. Nucleic Acids Res 35(22):7485–7496
Hummel TR, Chow LM, Fouladi M, Franz D (2013) Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies. Paediatr Drugs 15(1):29–42
Jiang YS, Wang FR (2013) Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neurooncol 114(1):25–32
Kim DY, Rho JM (2008) The ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care 11(2):113–120
Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, Freedland SJ (2012) Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int 110(7):1062–1069
Klement RJ, Champ CE (2014) Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev 33(1):217–29
Kobow K, Kaspi A, Harikrishnan KN, Kiese K, Ziemann M, Khurana I, Fritzsche I, Hauke J, Hahnen E, Coras R, Muhlebner A, El-Osta A, Blumcke I (2013) Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol 126(5):741–756
Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1:52
Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD (2010) Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 70(4):1564–1572
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R, Longo VD (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4(124):124ra27
Li HF, Kim JS, Waldman T (2009) Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4:43
Li W, Guo F, Wang P, Hong S, Zhang C (2014) miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med 14(1):185–195
Liang BC, Grootveld M (2011) The importance of mitochondria in the tumourigenic phenotype: gliomas as the paradigm (review). Int J Mol Med 27(2):159–171
Los M, Maddika S, Erb B, Schulze-Osthoff K (2009) Switching Akt: from survival signaling to deadly response. Bioessays 31(5):492–495
Maalouf M, Sullivan PG, Davis L, Kim DY, Rho JM (2007) Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145(1):256–264
Maalouf M, Rho JM, Mattson MP (2009) The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 59(2):293–315
Magee BA, Potezny N, Rofe AM, Conyers RA (1979) The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci 57(5):529–539
Marie SK, Shinjo SM (2011) Metabolism and brain cancer. Clinics (SaoPaulo) 66(Suppl 1):33–43
Marsh J, Mukherjee P, Seyfried TN (2008) Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 14(23):7751–7762
Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38(3):271–291
Maurer GD, Brucker DP, Bahr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J (2011) Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 11(315):315
Mavropoulos JC, Buschemeyer WC III, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ (2009) The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila) 2(6):557–565
Medova M, Aebersold DM, Zimmer Y (2013) The molecular crosstalk between the MET receptor tyrosine kinase and the DNA damage response-biological and clinical aspects. Cancers(Basel) 6(1):1–27
Morris AAM (2005) Cerebral ketone body metabolism. J Inherit Metab Dis 28:109–121
Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK (1999) Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 91(6):512–523
Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN (2002) Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 86(10):1615–1621
Mukherjee P, Abate LE, Seyfried TN (2004) Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10(16):5622–5629
Mulrooney TJ, Marsh J, Urits I, Seyfried TN, Mukherjee P (2011) Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS One 6(3), e18085
Munshi A, Ramesh R (2013) Mitogen-Activated Protein Kinases and Their Role in Radiation Response. Genes Cancer 4(9-10):401–408
Nebeling LC, Lerner E (1995) Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 95(6):693–697
Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14(2):202–208
Negi A, Ramarao P, Kumar R (2013) Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents. Mini Rev Med Chem 13(5):653–681
Nijsten MW, van Dam GM (2009) Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. Med Hypotheses 73(1):48–51
Obre E, Rossignol R (2015) Emerging concepts in bioenergetics and cancer research: Metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol 59C:167–181. doi:10.1016/j.biocel.2014.12.008
Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert. Opin. Investig, Drugs
Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, Bernstein BE (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344(6190):1396–1401
Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP (2010) Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123(2):333–344
Poff AM, Ari C, Seyfried TN, D'Agostino DP (2013) The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One 8(6), e65522
Puzio-Kuter AM (2011) The role of p53 in metabolic regulation. Genes Cancer 2(4):385–391
Qureshi IA, Mehler MF (2013) Developing epigenetic diagnostics and therapeutics for brain disorders. Trends Mol Med 19(12):732–741
Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD (2008) Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 105(24):8215–8220
Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD (2010) Fasting and differential chemotherapy protection in patients. Cell Cycle 9(22):4474–4476
Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN (2005) Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7(10):921–929
Robey RB, Hay N (2009) Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19(1):25–31
Rous P (1914) The influence of diet on transplanted and spontaneous mouse tumors. J Exp Med 20(5):433–451
Saenko Y, Cieslar-Pobuda A, Skonieczna M, Rzeszowska-Wolny J (2013) Changes of reactive oxygen and nitrogen species and mitochondrial functioning in human K562 and HL60 cells exposed to ionizing radiation. Radiat Res 180(4):360–366
Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC, Longo VD (2012) Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One 7(9), e44603
Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, Jin L, Champ CE, Zhao S, Lim M, Sotgia F, Camphausen K, Pestell RG, Mitchell JB, Lisanti MP, Simone NL (2013) Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 12(12):1955–1963
Sanli T, Steinberg GR, Singh G, Tsakiridis T (2014) AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 15(2):156–169
Santivasi WL, Xia F (2014) 2014. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal 21(2):251–9
Scheck AC, Abdelwahab MG, Stafford P, Kim DY, Iwai S, Preul MC, Rho JM (2011) Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. Cancer Res 70(8 Suppl):638, Ref Type: Abstract
Scheck AC, Abdelwahab MG, Fenton K, Stafford P (2012) The ketogenic diet for the treatment of glioma: Insights from genetic profiling. Epilepsy Res 100:327–337
Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123(9):3664–3671
Seyfried TN (2012) Cancer as a metabolic disease: on the origin, management and prevention of cancer. John Wiley and Sons Inc, Hoboken, NJ
Seyfried TN, Mukherjee P (2005) Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab 2:30–38
Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P (2003) Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89(7):1375–1382
Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P (2011) Metabolic management of brain cancer. Biochim Biophys Acta 1807(6):577–594
Seyfried TN, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P (2012) Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res 100(3):310–326
Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN (2010) Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro 2(3), e00038
Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le MN, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E (2013) Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339(6116):211–214
Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK (2014) Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab 2:18
Singh P, Alex JM, Bast F (2014) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 31(1):805
Skinner R, Trujillo A, Ma X, Beierle EA (2009) Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg 44(1):212–216
Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7:74
Stafstrom CE, Rho JM (2012) The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 3:59
Thompson HJ, McGinley JN, Spoelstra NS, Jiang W, Zhu Z, Wolfe P (2004) Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res 64(16):5643–5650
Tisdale MJ, Brennan RA (1983) Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer 47(2):293–297
Tisdale MJ, Brennan RA, Fearon KC (1987) Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer 56(1):39–43
Urits I, Mukherjee P, Meidenbauer J, Seyfried TN (2012) Dietary restriction promotes vessel maturation in a mouse astrocytoma. J Oncol 2012:264039
Vadlakonda L, Dash A, Pasupuleti M, Anil KK, Reddanna P (2013) The Paradox of Akt-mTOR Interactions. Front Oncol 3:165
van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, MacDonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583–593
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 1029–1033
Vanitallie TB, Nufert TH (2003) Ketones: metabolism's ugly duckling. Nutr Rev 61(10):327–341
Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr (2001) Ketone bodies, potential therapeutic uses. IUBMB Life 51(4):241–247
Venneti S, Thompson CB (2013) Metabolic modulation of epigenetics in gliomas. Brain Pathol 23(2):217–221
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P, Shi CH, Zhang W, Li YM, Fu Q, Zhu GF, Xue W, Lei YH, Gao JY, Wang JY, Shao C, Yi CG, Wang H (2013) Inhibition of both EGFR and IGF1R sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair. PLoS One 8(8), e68784
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530
Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297–308
Weinberg F, Chandel NS (2009) Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 66(23):3663–3673
Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 18(1):40–44
Weroha SJ, Haluska P (2012) The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 41(2):335–50, vi
Wolf A, Agnihotri S, Guha A (2010) Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1(7):552–562
Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, Scheck AC (2015) The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One 10(6):e0130357
Woolf EC, Stafford P, Abdelwahab MG, Fenton KE, Preul MC, Scheck AC (2013) The ketogenic diet potentiates radiation therapy in a mouse model of glioma: effects on inflammatory pathways and reactive oxygen species. Cancer Res 73:4441
Yang C, Sudderth J, Dang T, Bachoo RG, McDonald JG, DeBerardinis RJ (2009) Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69(20):7986–7993
Yun J, Johnson JL, Hanigan CL, Locasale JW (2012) Interactions between epigenetics and metabolism in cancers. Front Oncol 2:163
Zhang H, Gu C, Yu J, Wang Z, Yuan X, Yang L, Wang J, Jia Y, Liu J, Liu F (2014) Radiosensitization of glioma cells by TP53-induced glycolysis and apoptosis regulator knockdown is dependent on thioredoxin-1 nuclear translocation. Free Radic Biol Med 69C:239–248
Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4:5
Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN (2010) Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab 7:33–53
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Brooks, K.S., Woolf, E.C., Scheck, A.C. (2016). The Ketogenic Diet as an Adjuvant Therapy for Brain Tumors and Other Cancers. In: Ullah, M., Ahmad, A. (eds) Critical Dietary Factors in Cancer Chemoprevention. Springer, Cham. https://doi.org/10.1007/978-3-319-21461-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-21461-0_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21460-3
Online ISBN: 978-3-319-21461-0
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)